$Jaguar Health (JAGX.US)$ Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025 Wednesday, 22nd January at 9:00 am Trial taking place at Sheikh Khalifa Medical City, a flagship tertiary hospital in the United Arab Emirates POC data generated from this study could potentially lead to reimbursed early patient ac...
$Jaguar Health (JAGX.US)$ FDA Approves Orphan-Drug Designation for Jaguar Health's Crofelemer for Treatment of Diarrhea in Cholera Tuesday, 17th December at 8:30 am World Health Organization (WHO) has classified the global resurgence of cholera at the highest internal level for emergencies; 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio ch...
$Jaguar Health (JAGX.US)$ Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS) Thursday, 12th December at 9:00 am Adult patients with breast cancer are a prespecified subgroup of the recently conducted phase 3 OnTarget trial evaluating crofelemer for prophylaxis of CTD The majority of patients in the OnTarget placebo group on abemaciclib and pertuzumab-based the...
Jaguar Health Stock Forum
Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025
Wednesday, 22nd January at 9:00 am
Trial taking place at Sheikh Khalifa Medical City, a flagship tertiary hospital in the United Arab Emirates
POC data generated from this study could potentially lead to reimbursed early patient ac...
FDA Approves Orphan-Drug Designation for Jaguar Health's Crofelemer for Treatment of Diarrhea in Cholera
Tuesday, 17th December at 8:30 am
World Health Organization (WHO) has classified the global resurgence of cholera at the highest internal level for emergencies; 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide
Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio ch...
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)
Thursday, 12th December at 9:00 am
Adult patients with breast cancer are a prespecified subgroup of the recently conducted phase 3 OnTarget trial evaluating crofelemer for prophylaxis of CTD
The majority of patients in the OnTarget placebo group on abemaciclib and pertuzumab-based the...
No comment yet